Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score emphasizes finding undervalued stocks based on financial ratios [3] - Growth Score focuses on a company's financial health and future growth potential [4] - Momentum Score capitalizes on existing trends in stock prices and earnings estimates [5] - VGM Score combines all three styles to identify stocks with the best overall characteristics [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investment decisions [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41%, significantly outperforming the S&P 500 [8] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [10] Stock Highlight: PTC Inc. - PTC Inc., based in Boston, MA, is a software provider specializing in digital technologies for engineering and production [12] - Currently rated 3 (Hold) with a VGM Score of B, PTC has a Momentum Style Score of A and has seen a 16.4% increase in shares over the past four weeks [12][13] - Recent upward revisions in earnings estimates indicate a positive outlook, with the Zacks Consensus Estimate rising by $0.15 to $5.97 per share [13]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What a ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving PTC Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On May 5, 2025, PTC announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease patients, which met its primary endpoint of reducing blood Huntingtin protein levels with a p-value of less than 0.0001 at Week 12 [3] - Analysts suggest that PTC may need to conduct a Phase 3 study to confirm whether the treatment effectively slows Huntington's disease [3] Group 2: Market Reaction - Following the announcement of the study results, PTC's stock price dropped by $9.30 per share, or 18.62%, closing at $40.65 per share on May 5, 2025 [4]

Core Insights - The focus is on sustainable wealth growth through investments in R&D biotech [1] - The author expresses a personal beneficial long position in QURE shares, indicating confidence in the company's potential [1] Company and Industry Summary - The article emphasizes the importance of research and development in the biotechnology sector as a means to achieve sustainable investment returns [1] - The author highlights the relevance of their academic background in Cell Physiology and Bio-organic Chemistry to their investment strategy in biotech [1]

Core Viewpoint - PTC Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following the announcement of Phase 2 study results for its treatment of Huntington's disease, which led to a significant drop in stock price [1][2][3]. Group 1: Company Developments - PTC announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease patients, achieving its primary endpoint of reducing blood Huntingtin protein levels with a p-value of less than 0.0001 at Week 12 [2]. - Despite meeting the primary endpoint, analysts suggest that a Phase 3 study may be necessary to confirm the treatment's efficacy in slowing the progression of Huntington's disease [2]. Group 2: Market Reaction - Following the announcement of the study results, PTC's stock price fell by $9.30 per share, representing an 18.62% decline, closing at $40.65 per share on May 5, 2025 [3].

Core Insights - PTC Therapeutics reported strong revenue performance of $190 million for the first quarter of 2025, with a significant cash position exceeding $2 billion as of March 31, 2025, supporting ongoing commercial and R&D activities [1][8]. Financial Performance - Total net product and royalty revenue for Q1 2025 was $190 million, a decrease from $208.8 million in Q1 2024 [5]. - Revenue from the DMD franchise was $134 million, with Translarna™ contributing $86 million and Emflaza® contributing $48 million [5]. - Collaboration and license revenue included $986.2 million from the PTC518 agreement with Novartis, which closed in January 2025 [5][7]. - Net income for Q1 2025 was $866.6 million, compared to a net loss of $91.6 million in Q1 2024 [8]. Regulatory and Clinical Updates - Positive CHMP opinion for Sephience™ (sepiapterin) received on April 25, 2025, with an expected European Commission adoption in approximately two months [5]. - NDA for Sephience is under review by the FDA, with a target action date of July 29, 2025 [5]. - NDA for vatiquinone accepted and granted Priority Review by the FDA, with a target action date of August 19, 2025 [5]. - Phase 2 PIVOT-HD study for PTC518 met primary endpoint of dose-dependent blood HTT lowering at Week 12, with favorable safety and tolerability [5]. Guidance and Future Outlook - PTC anticipates full-year 2025 revenue between $650 million and $800 million, including in-line products and potential new launches [8]. - Full-year 2025 GAAP R&D and SG&A expenses are projected to be between $805 million and $835 million [8]. - Non-GAAP R&D and SG&A expenses are expected to be between $730 million and $760 million, excluding estimated non-cash, stock-based compensation of $75 million [8].

Core Insights - PTC Therapeutics announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) for Huntington's disease, achieving its primary endpoint of reducing blood HTT protein levels with significant statistical significance [1][2] Study Results - The study demonstrated a reduction in blood HTT protein levels of 23% at the 5mg dose and 39% at the 10mg dose for Stage 2 patients, while Stage 3 patients showed a 36% reduction at the 10mg dose [4] - The treatment exhibited favorable safety and tolerability across all dose levels and disease stages, with no serious adverse events reported [5] Clinical Implications - There were observed dose-dependent trends in clinical scales for Stage 2 patients, including improvements in the Composite Unified Huntington's Disease Rating Scale (cUHDRS) and Total Motor Score (TMS) [4] - For Stage 3 patients, the 5mg dose showed favorable trends compared to placebo, indicating potential differences in treatment effects between stages [5] Long-term Data - 24-month treatment data indicated dose-dependent trends on cUHDRS, Total Function Capacity (TFC), and Symbol Digit Modalities Test (SDMT) subscales, with a notable lowering of plasma NfL levels at both 5mg and 10mg doses [6] Market Reaction - Following the announcement, PTC Therapeutics' stock fell by 18.60% to $40.65, reflecting investor concerns regarding the differing treatment effects observed in Stage 3 patients [5][7]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 PTC Inc. (Exact name of registrant as specified in its charter) Massachusetts 04-2866152 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 121 Seaport Boulevard, Boston, MA 02210 (Address of principal executive offices, including zip code) (781) 370-5000 For the quarte ...

Core Viewpoint - PTC Inc. reported strong second-quarter fiscal 2025 results, with non-GAAP EPS of $1.79, exceeding estimates by 29.7%, and revenues of $636 million, up 6% year over year, driven by robust performance across key business areas despite a challenging environment [1][2]. Financial Performance - Non-GAAP EPS for the prior-year quarter was $1.46, indicating significant growth [1]. - Revenues of $636 million surpassed the consensus estimate by 4.6%, with management projecting revenues between $590 million and $620 million for the upcoming quarter [1][10]. - Recurring revenues reached $601.5 million, a 6.6% increase year over year [3]. - License revenues, accounting for 40% of total revenues, were $254.4 million, up 8.6% from the previous year [4]. - Support and cloud services revenues, making up 55.5% of total revenues, increased by 4.9% to $353 million [4]. - Professional services revenues decreased by 10.3% to $29 million, representing 4.5% of total revenues [4]. Product Group Performance - PLM revenues were $396 million, reflecting a 6% year-over-year increase, while CAD revenues were $240 million, up 5% year over year [5]. ARR Performance - Annualized recurring revenues (ARR) reached $2.29 billion, a 10% increase year over year, with constant currency ARR at $2.326 billion [6]. - PLM and CAD ARR were $1,429 million and $897 million, rising 11% and 8% year over year, respectively [6]. Operating Details - Total operating expenses decreased by 2.2% year over year to $306.6 million [7]. - Non-GAAP operating income rose by 17.8% year over year to $299.3 million, with an operating margin increase of 490 basis points to 47% [7]. Balance Sheet & Cash Flow - As of March 31, 2025, cash and cash equivalents were $235 million, up from $196 million as of December 31, 2024 [9]. - Total debt decreased to $1.39 billion from $1.544 billion [9]. - Cash provided by operating activities was $281 million, compared to $251 million in the prior-year quarter [9]. - Free cash flow increased to $279 million from $247 million year over year [9]. Future Guidance - For the third quarter of fiscal 2025, PTC estimates revenues between $560 million and $600 million, with non-GAAP EPS projected in the range of $1.05 to $1.30 [10]. - Full fiscal 2025 revenue projections are now between $2,445 million and $2,565 million, indicating a year-over-year rise of 6-12% [11]. - Non-GAAP EPS for fiscal 2025 is estimated to be between $5.80 and $6.55, suggesting a 14-29% increase [11]. - Cash from operations is projected to be between $855 million and $865 million, indicating a 14% to 15% year-over-year increase [12].

Group 1 - PTC Inc. reported quarterly earnings of $1.79 per share, exceeding the Zacks Consensus Estimate of $1.38 per share, and up from $1.46 per share a year ago, representing an earnings surprise of 29.71% [1] - The company posted revenues of $636.37 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.62% and increasing from $603.07 million year-over-year [2] - PTC Inc. has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates three times in the same period [2] Group 2 - The stock has underperformed the market, losing about 16.4% since the beginning of the year compared to the S&P 500's decline of 5.5% [3] - The current consensus EPS estimate for the coming quarter is $1.46 on revenues of $623.14 million, and for the current fiscal year, it is $5.75 on revenues of $2.48 billion [7] - The Zacks Industry Rank for Computer - Software is in the top 31% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]